Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 239

1.

Sphingosine-1-Phosphate Receptor 1 Activity Promotes Tumor Growth by Amplifying VEGF-VEGFR2 Angiogenic Signaling.

Balaji Ragunathrao VA, Anwar M, Akhter MZ, Chavez A, Mao Y, Natarajan V, Lakshmikanthan S, Chrzanowska-Wodnicka M, Dudek AZ, Claesson-Welsh L, Kitajewski JK, Wary KK, Malik AB, Mehta D.

Cell Rep. 2019 Dec 10;29(11):3472-3487.e4. doi: 10.1016/j.celrep.2019.11.036.

PMID:
31825830
2.

Myc-dependent endothelial proliferation is controlled by phosphotyrosine 1212 in VEGF receptor-2.

Testini C, Smith RO, Jin Y, Martinsson P, Sun Y, Hedlund M, Sáinz-Jaspeado M, Shibuya M, Hellström M, Claesson-Welsh L.

EMBO Rep. 2019 Nov 5;20(11):e47845. doi: 10.15252/embr.201947845. Epub 2019 Sep 23.

3.

Caspase-8 modulates physiological and pathological angiogenesis during retina development.

Tisch N, Freire-Valls A, Yerbes R, Paredes I, La Porta S, Wang X, Martín-Pérez R, Castro L, Wong WW, Coultas L, Strilic B, Gröne HJ, Hielscher T, Mogler C, Adams RH, Heiduschka P, Claesson-Welsh L, Mazzone M, López-Rivas A, Schmidt T, Augustin HG, Ruiz de Almodovar C.

J Clin Invest. 2019 Dec 2;129(12):5092-5107. doi: 10.1172/JCI122767.

4.

What is normal? Apelin and VEGFA, drivers of tumor vessel abnormality.

Claesson-Welsh L.

EMBO Mol Med. 2019 Aug;11(8):e10892. doi: 10.15252/emmm.201910892. Epub 2019 Jul 18.

5.

Fine-Tuning of Sox17 and Canonical Wnt Coordinates the Permeability Properties of the Blood-Brain Barrier.

Corada M, Orsenigo F, Bhat GP, Conze LL, Breviario F, Cunha SI, Claesson-Welsh L, Beznoussenko GV, Mironov AA, Bacigaluppi M, Martino G, Pitulescu ME, Adams RH, Magnusson P, Dejana E.

Circ Res. 2019 Feb 15;124(4):511-525. doi: 10.1161/CIRCRESAHA.118.313316.

6.

Alk1 (Activin Receptor-Like Kinase 1) and Vascular Hyperpermeability in Diabetic Retinopathy.

Claesson-Welsh L.

Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1673-1675. doi: 10.1161/ATVBAHA.118.311365. No abstract available.

PMID:
30354200
7.

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.

Mitran B, Güler R, Roche FP, Lindström E, Selvaraju RK, Fleetwood F, Rinne SS, Claesson-Welsh L, Tolmachev V, Ståhl S, Orlova A, Löfblom J.

Theranostics. 2018 Aug 7;8(16):4462-4476. doi: 10.7150/thno.24395. eCollection 2018.

8.

VEGF receptor-2/neuropilin 1 trans-complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival.

Morin E, Sjöberg E, Tjomsland V, Testini C, Lindskog C, Franklin O, Sund M, Öhlund D, Kiflemariam S, Sjöblom T, Claesson-Welsh L.

J Pathol. 2018 Nov;246(3):311-322. doi: 10.1002/path.5141. Epub 2018 Sep 4.

9.

Intravital imaging-based analysis tools for vessel identification and assessment of concurrent dynamic vascular events.

Honkura N, Richards M, Laviña B, Sáinz-Jaspeado M, Betsholtz C, Claesson-Welsh L.

Nat Commun. 2018 Jul 16;9(1):2746. doi: 10.1038/s41467-018-04929-8.

10.

Leukocyte Differentiation by Histidine-Rich Glycoprotein/Stanniocalcin-2 Complex Regulates Murine Glioma Growth through Modulation of Antitumor Immunity.

Roche FP, Pietilä I, Kaito H, Sjöström EO, Sobotzki N, Noguer O, Skare TP, Essand M, Wollscheid B, Welsh M, Claesson-Welsh L.

Mol Cancer Ther. 2018 Sep;17(9):1961-1972. doi: 10.1158/1535-7163.MCT-18-0097. Epub 2018 Jun 26.

11.

Shear Stress and VE-Cadherin.

Caolo V, Peacock HM, Kasaai B, Swennen G, Gordon E, Claesson-Welsh L, Post MJ, Verhamme P, Jones EAV.

Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):2174-2183. doi: 10.1161/ATVBAHA.118.310823.

PMID:
29930007
12.

Cytokines regulating lymphangiogenesis.

Sáinz-Jaspeado M, Claesson-Welsh L.

Curr Opin Immunol. 2018 Aug;53:58-63. doi: 10.1016/j.coi.2018.04.003. Epub 2018 Apr 20. Review.

PMID:
29680577
13.

U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.

Glimelius B, Melin B, Enblad G, Alafuzoff I, Beskow A, Ahlström H, Bill-Axelson A, Birgisson H, Björ O, Edqvist PH, Hansson T, Helleday T, Hellman P, Henriksson K, Hesselager G, Hultdin M, Häggman M, Höglund M, Jonsson H, Larsson C, Lindman H, Ljuslinder I, Mindus S, Nygren P, Pontén F, Riklund K, Rosenquist R, Sandin F, Schwenk JM, Stenling R, Stålberg K, Stålberg P, Sundström C, Thellenberg Karlsson C, Westermark B, Bergh A, Claesson-Welsh L, Palmqvist R, Sjöblom T.

Acta Oncol. 2018 Feb;57(2):187-194. doi: 10.1080/0284186X.2017.1337926. Epub 2017 Jun 20.

PMID:
28631533
14.

Highly sensitive and specific protein detection via combined capillary isoelectric focusing and proximity ligation.

Padhan N, Yan J, Boge A, Scrivener E, Birgisson H, Zieba A, Gullberg M, Kamali-Moghaddam M, Claesson-Welsh L, Landegren U.

Sci Rep. 2017 May 4;7(1):1490. doi: 10.1038/s41598-017-01516-7.

15.

Case-specific potentiation of glioblastoma drugs by pterostilbene.

Schmidt L, Baskaran S, Johansson P, Padhan N, Matuszewski D, Green LC, Elfineh L, Wee S, Häggblad M, Martens U, Westermark B, Forsberg-Nilsson K, Uhrbom L, Claesson-Welsh L, Andäng M, Sintorn IM, Lundgren B, Lönnstedt I, Krona C, Nelander S.

Oncotarget. 2016 Nov 8;7(45):73200-73215. doi: 10.18632/oncotarget.12298.

16.

High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer.

Padhan N, Nordling TE, Sundström M, Åkerud P, Birgisson H, Nygren P, Nelander S, Claesson-Welsh L.

BMC Cancer. 2016 Aug 25;16(1):683. doi: 10.1186/s12885-016-2725-z.

17.

In Situ Proximity Ligation Assay (In Situ PLA) to Assess PTP-Protein Interactions.

Koch S, Helbing I, Böhmer SA, Hayashi M, Claesson-Welsh L, Söderberg O, Böhmer FD.

Methods Mol Biol. 2016;1447:217-42. doi: 10.1007/978-1-4939-3746-2_13.

PMID:
27514809
18.

Mechanisms and regulation of endothelial VEGF receptor signalling.

Simons M, Gordon E, Claesson-Welsh L.

Nat Rev Mol Cell Biol. 2016 Oct;17(10):611-25. doi: 10.1038/nrm.2016.87. Epub 2016 Jul 27. Review.

PMID:
27461391
19.

The endothelial adaptor molecule TSAd is required for VEGF-induced angiogenic sprouting through junctional c-Src activation.

Gordon EJ, Fukuhara D, Weström S, Padhan N, Sjöström EO, van Meeteren L, He L, Orsenigo F, Dejana E, Bentley K, Spurkland A, Claesson-Welsh L.

Sci Signal. 2016 Jul 19;9(437):ra72. doi: 10.1126/scisignal.aad9256.

PMID:
27436360
20.

VEGF receptor signal transduction - A brief update.

Claesson-Welsh L.

Vascul Pharmacol. 2016 Nov;86:14-17. doi: 10.1016/j.vph.2016.05.011. Epub 2016 Jun 4. Review.

PMID:
27268035
21.

VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread.

Li X, Padhan N, Sjöström EO, Roche FP, Testini C, Honkura N, Sáinz-Jaspeado M, Gordon E, Bentley K, Philippides A, Tolmachev V, Dejana E, Stan RV, Vestweber D, Ballmer-Hofer K, Betsholtz C, Pietras K, Jansson L, Claesson-Welsh L.

Nat Commun. 2016 Mar 23;7:11017. doi: 10.1038/ncomms11017.

22.

Tracheobronchial transplantation: The Royal Swedish Academy of Sciences' concerns.

Claesson-Welsh L, Hansson GK; Royal Swedish Academy of Sciences.

Lancet. 2016 Mar 5;387(10022):942. doi: 10.1016/S0140-6736(16)00520-1. Epub 2016 Feb 23. No abstract available.

PMID:
26921133
23.

Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling.

Fleetwood F, Güler R, Gordon E, Ståhl S, Claesson-Welsh L, Löfblom J.

Cell Mol Life Sci. 2016 Apr;73(8):1671-83. doi: 10.1007/s00018-015-2088-7. Epub 2015 Nov 9.

PMID:
26552422
24.

Identification and characterization of VEGF-A-responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans.

Massena S, Christoffersson G, Vågesjö E, Seignez C, Gustafsson K, Binet F, Herrera Hidalgo C, Giraud A, Lomei J, Weström S, Shibuya M, Claesson-Welsh L, Gerwins P, Welsh M, Kreuger J, Phillipson M.

Blood. 2015 Oct 22;126(17):2016-26. doi: 10.1182/blood-2015-03-631572. Epub 2015 Aug 18.

25.

Vascular permeability--the essentials.

Claesson-Welsh L.

Ups J Med Sci. 2015;120(3):135-43. doi: 10.3109/03009734.2015.1064501. Epub 2015 Jul 29. Review.

26.

Histidine-rich glycoprotein blocks collagen-binding integrins and adhesion of endothelial cells through low-affinity interaction with α2 integrin.

Roche F, Sipilä K, Honjo S, Johansson S, Tugues S, Heino J, Claesson-Welsh L.

Matrix Biol. 2015 Oct;48:89-99. doi: 10.1016/j.matbio.2015.06.002. Epub 2015 Jun 5.

PMID:
26051322
27.

p73 is required for endothelial cell differentiation, migration and the formation of vascular networks regulating VEGF and TGFβ signaling.

Fernandez-Alonso R, Martin-Lopez M, Gonzalez-Cano L, Garcia S, Castrillo F, Diez-Prieto I, Fernandez-Corona A, Lorenzo-Marcos ME, Li X, Claesson-Welsh L, Marques MM, Marin MC.

Cell Death Differ. 2015 Aug;22(8):1287-99. doi: 10.1038/cdd.2014.214. Epub 2015 Jan 9.

28.

Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes.

Tugues S, Roche F, Noguer O, Orlova A, Bhoi S, Padhan N, Akerud P, Honjo S, Selvaraju RK, Mazzone M, Tolmachev V, Claesson-Welsh L.

PLoS One. 2014 Sep 22;9(9):e107483. doi: 10.1371/journal.pone.0107483. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0118636.

29.

The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesis.

Bentley K, Franco CA, Philippides A, Blanco R, Dierkes M, Gebala V, Stanchi F, Jones M, Aspalter IM, Cagna G, Weström S, Claesson-Welsh L, Vestweber D, Gerhardt H.

Nat Cell Biol. 2014 Apr;16(4):309-21. doi: 10.1038/ncb2926. Epub 2014 Mar 23.

PMID:
24658686
30.

NRP1 presented in trans to the endothelium arrests VEGFR2 endocytosis, preventing angiogenic signaling and tumor initiation.

Koch S, van Meeteren LA, Morin E, Testini C, Weström S, Björkelund H, Le Jan S, Adler J, Berger P, Claesson-Welsh L.

Dev Cell. 2014 Mar 31;28(6):633-46. doi: 10.1016/j.devcel.2014.02.010. Epub 2014 Mar 20.

31.

Pulmonary lymphangiectasia resulting from vascular endothelial growth factor-C overexpression during a critical period.

Yao LC, Testini C, Tvorogov D, Anisimov A, Vargas SO, Baluk P, Pytowski B, Claesson-Welsh L, Alitalo K, McDonald DM.

Circ Res. 2014 Feb 28;114(5):806-22. doi: 10.1161/CIRCRESAHA.114.303119. Epub 2014 Jan 15.

32.

Tetraspanin CD63 promotes vascular endothelial growth factor receptor 2-β1 integrin complex formation, thereby regulating activation and downstream signaling in endothelial cells in vitro and in vivo.

Tugues S, Honjo S, König C, Padhan N, Kroon J, Gualandi L, Li X, Barkefors I, Thijssen VL, Griffioen AW, Claesson-Welsh L.

J Biol Chem. 2013 Jun 28;288(26):19060-71. doi: 10.1074/jbc.M113.468199. Epub 2013 Apr 30.

33.

VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation.

Hayashi M, Majumdar A, Li X, Adler J, Sun Z, Vertuani S, Hellberg C, Mellberg S, Koch S, Dimberg A, Koh GY, Dejana E, Belting HG, Affolter M, Thurston G, Holmgren L, Vestweber D, Claesson-Welsh L.

Nat Commun. 2013;4:1672. doi: 10.1038/ncomms2683.

34.

Introduction to the ECR special angiogenesis issue.

Claesson-Welsh L, Gerhardt H.

Exp Cell Res. 2013 May 15;319(9):1239. doi: 10.1016/j.yexcr.2013.03.014. Epub 2013 Mar 15. No abstract available.

PMID:
23506975
35.

Hypoxia-induced arterial differentiation requires adrenomedullin and notch signaling.

Lanner F, Lee KL, Ortega GC, Sohl M, Li X, Jin S, Hansson EM, Claesson-Welsh L, Poellinger L, Lendahl U, Farnebo F.

Stem Cells Dev. 2013 May 1;22(9):1360-9. doi: 10.1089/scd.2012.0259. Epub 2013 Feb 12.

PMID:
23379656
36.

VEGFA and tumour angiogenesis.

Claesson-Welsh L, Welsh M.

J Intern Med. 2013 Feb;273(2):114-27. doi: 10.1111/joim.12019. Review.

37.

Introduction to symposium on vascular biology, metabolism and cancer.

Claesson-Welsh L.

J Intern Med. 2013 Feb;273(2):112-3. doi: 10.1111/joim.12015. No abstract available.

38.

Receptor talk and tumor cell walk in glioblastoma.

Claesson-Welsh L.

Cancer Cell. 2012 Jul 10;22(1):1-2. doi: 10.1016/j.ccr.2012.06.011.

39.

Signal transduction by vascular endothelial growth factor receptors.

Koch S, Claesson-Welsh L.

Cold Spring Harb Perspect Med. 2012 Jul;2(7):a006502. doi: 10.1101/cshperspect.a006502. Review.

40.

VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd.

Sun Z, Li X, Massena S, Kutschera S, Padhan N, Gualandi L, Sundvold-Gjerstad V, Gustafsson K, Choy WW, Zang G, Quach M, Jansson L, Phillipson M, Abid MR, Spurkland A, Claesson-Welsh L.

J Exp Med. 2012 Jul 2;209(7):1363-77. doi: 10.1084/jem.20111343. Epub 2012 Jun 11.

41.

Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization.

Tugues S, Honjo S, König C, Noguer O, Hedlund M, Botling J, Deschoemaeker S, Wenes M, Rolny C, Jahnen-Dechent W, Mazzone M, Claesson-Welsh L.

Cancer Res. 2012 Apr 15;72(8):1953-63. doi: 10.1158/0008-5472.CAN-11-2194. Epub 2012 Feb 28.

42.

Blood vessels as targets in tumor therapy.

Claesson-Welsh L.

Ups J Med Sci. 2012 May;117(2):178-86. doi: 10.3109/03009734.2012.660550. Epub 2012 Feb 21. Review.

43.

Functional overlap between chondroitin and heparan sulfate proteoglycans during VEGF-induced sprouting angiogenesis.

Le Jan S, Hayashi M, Kasza Z, Eriksson I, Bishop JR, Weibrecht I, Heldin J, Holmborn K, Jakobsson L, Söderberg O, Spillmann D, Esko JD, Claesson-Welsh L, Kjellén L, Kreuger J.

Arterioscler Thromb Vasc Biol. 2012 May;32(5):1255-63. doi: 10.1161/ATVBAHA.111.240622. Epub 2012 Feb 16.

44.

Analysis of VEGF--a regulated gene expression in endothelial cells to identify genes linked to angiogenesis.

Rivera CG, Mellberg S, Claesson-Welsh L, Bader JS, Popel AS.

PLoS One. 2011;6(9):e24887. doi: 10.1371/journal.pone.0024887. Epub 2011 Sep 13.

45.

Signal transduction by vascular endothelial growth factor receptors.

Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L.

Biochem J. 2011 Jul 15;437(2):169-83. doi: 10.1042/BJ20110301. Review.

PMID:
21711246
46.

Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.

Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L.

Mol Aspects Med. 2011 Apr;32(2):88-111. doi: 10.1016/j.mam.2011.04.004. Epub 2011 May 6. Review.

PMID:
21565214
47.

HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.

Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, Vinckier S, Dresselaer T, Åkerud P, De Mol M, Salomäki H, Phillipson M, Wyns S, Larsson E, Buysschaert I, Botling J, Himmelreich U, Van Ginderachter JA, De Palma M, Dewerchin M, Claesson-Welsh L, Carmeliet P.

Cancer Cell. 2011 Jan 18;19(1):31-44. doi: 10.1016/j.ccr.2010.11.009. Epub 2011 Jan 6.

48.

Gremlin: vexing VEGF receptor agonist.

Claesson-Welsh L.

Blood. 2010 Nov 4;116(18):3386-7. doi: 10.1182/blood-2010-09-299412.

PMID:
21051566
49.

ADAM-mediated shedding, a new flavor in angiogenesis regulation.

Claesson-Welsh L.

Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2087-8. doi: 10.1161/ATVBAHA.110.215285. No abstract available.

PMID:
20962296
50.

A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression.

Geretti E, van Meeteren LA, Shimizu A, Dudley AC, Claesson-Welsh L, Klagsbrun M.

Mol Cancer Res. 2010 Aug;8(8):1063-73. doi: 10.1158/1541-7786.MCR-10-0157. Epub 2010 Jul 22.

Supplemental Content

Loading ...
Support Center